GlassScriptPhysician profile
Missale Solomon
NPI 1245492693
$4,230.53
in general payments reported to CMS, 2019-2025
32 companies · $858 in 2025
The $858 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $163 · 2021: $285 · 2022: $431 · 2023: $916 · 2024: $1,180 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,924 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,924.41 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,023.49 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $628.26 | 2019-2025 | Stelara, Tremfya, Remicade |
| Abbvie INC. | $503.77 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $432.13 | 2021-2025 | |
| Celgene Corporation | $338.06 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.67 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $130.05 | 2025 | Livdelzi |
| Qol Medical, LLC | $98.21 | 2019-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $91.01 | 2019-2024 | Injectafer |
| Aimmune Therapeutics, INC. | $78.55 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $76.43 | 2019-2023 | Ocaliva |
| Madrigal Pharmaceuticals | $62.24 | 2024-2025 | Resmetirom, Rezdiffra |
| Genzyme Corporation | $49.11 | 2023-2024 | |
| Romark Laboratories, Lc | $46.98 | 2019-2020 | |
| Ardelyx, INC. | $46.81 | 2024-2025 | Ibsrela |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $42.30 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $41.25 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $33.84 | 2025 | Tremfya |
| Braintree Laboratories, INC. | $32.72 | 2019 | |
| Merck Sharp & Dohme LLC | $31.93 | 2021 | |
| Amgen INC. | $31.55 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $30.90 | 2022 | |
| Ferring Pharmaceuticals INC. | $25.46 | 2019 | |
| Lilly USA, LLC | $24.00 | 2025 | Omvoh |
| Celltrion USA INC. | $21.29 | 2025 | Vegzelma |
| Capsovision, INC. | $19.86 | 2024 | Capsocam Plus |
| E.R. Squibb & Sons, L.L.C. | $19.64 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.77 | 2024 | Givlaari |
| Novo Nordisk INC | $16.35 | 2025 | Wegovy |
| Shionogi INC | $15.64 | 2020 | |
| Ironwood Pharmaceuticals, INC | $15.29 | 2019 | |
| Shire North American Group INC | $13.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Missale Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.